 SAN DIEGO, March 28, 2021 PRNewswire -- Johnson Fistel, LLP is investigating potential claims on behalf of Zynerba Pharmaceuticals, Inc. NASDAQ: ZYNE Zynerba or the Company against certain of its officers and directors. Specifically, a class-action lawsuit pending in the Eastern District of Pennsylvania against Zynerba and certain of its current and former officers recently survived defendants attempts to dismiss the case. 